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There is very often a great gap between the performance of oral drug delivery 
systems in vitro and in vivo. During the last decade modern high resolution 
and/or real time imaging techniques like Magnetic Marker Monitoring (MMM) [1] 
or Magnetic Resonance Imaging (MRI) [2, 3] have provided new insights into 
the in vivo performance of drug delivery systems and their interaction with the 
physiology of the gastrointestinal tract. The physiological conditions for drug 
absorption along the gastrointestinal tract are far from being constant. This 
applies to the expression of transport proteins and metabolizing enzymes as 
well as for the luminal conditions [3, 4]. Accordingly, gastrointestinal passage of 
a drug delivery system plays a crucial role for drug absorption. Gastrointestinal 
transit is also not a constant process. It is strongly controlled by feedback 
mechanisms that involve neuronal and hormonal signal pathways. In contrast to 
widespread assumption, transit times through all gastrointestinal organs, i. e. 
stomach, small intestine and colon, are highly variable. Gastric residence times 
are in general dependent on the energy content of the gastric filling. The rate of 
gastric emptying under fed conditions is controlled by the energy content of the 
meal, the energy requirement of the body and feedback mechanisms like the 
ileal brake mechanism. Furthermore, the rate of gastric emptying under fed 
conditions is also influenced by particle size. As a consequence, the emptying 
of drug substances from the digesting stomach is dependent on three main 
factors, the gastric emptying rate of the meal, the intragastric distribution of the 
drug and the particle size of the formulation. Examples for the in vivo behavior 
of different oral controlled release systems and resulting drug plasma 
concentration profiles will be shown and discussed.  
[1]  Weitschies W, Blume H, Mönnikes H. Magnetic marker monitoring: high resolution real-time tracking of 
oral solid dosage forms in the gastrointestinal tract. Eur J Pharm Biopharm. 2010; 74: 93–101. 
doi:10.1016/j.ejpb.2009.07.007 
[2]  Faas H, Schwizer W, Feinle C, Lengsfeld H, de Smidt C, Boesiger P, Fried M, Rades T. Monitoring the 
intragastric distribution of a colloidal drug carrier model by magnetic resonance imaging. Pharm Res. 
2001; 18: 460–466. doi:10.1023/A:1011098125916 
[3]  Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Mönnikes H, Hosten N, Weitschies W. Intestinal 
fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment 
Pharmacol Ther. 2005; 22: 971–979. doi:10.1111/j.1365-2036.2005.02683.x 
[4]  Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Grasjö J, Kindmark A, Artursson P. 
Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC 
transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006; 29: 269–227. 
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Several inter-related issues relevant for the development of novel drug delivery 
systems are covered in the talk. They encompass:  
(i) Release from electrospun nanofibers. The present work shows that solid-
state diffusion may not be the primary mechanism at play. In such cases the 
release rate of low molecular weight compounds can be explained by 
desorption of the embedded compound from nanopores in the fibers, or from 
the outer surface of the fibers. In addition, the desorption-limited release 
mechanism is supported by the results for release of two model protein (high 
molecular weight) compounds from electrospun polycaprolactone (PCL) 
nanofiber mats. The studied compounds were bovine serum albumin (BSA) and 
an anti-integrin antibody (AI). The results are consistent with protein release 
mechanism dominated by desorption from the polymer surface.  
(ii)  Nanofluidics for long-term drug delivery. Macroscopically long bundles of 
parallel straight carbon nanotubes/nanopores produced by either co-
electrospinning or the nanofiber template casting method were studied as 
possible tools for this purpose. These nanopores have diameters in the range of 
about 300 nm to 1 μm and lengths up to 1 cm.  
(iii) Nanochannels were also used to polymerize sufficiently monodisperse 
monolithic and core-shell thermo-responsive Poly(N-isopropyl acrylamide) 
(PNIPAM) nanoparticles of the order of 400 nm dia. at the rate of 10
7 particles 
per sec. During their formation, the nanoparticles were loaded with a model 
fluorescent admixture to study its encapsulation in these promising drug 
carriers. The release kinetics from the nanoparticles was studied under the 
conditions of thermal stimulation.  
(iv) Filling nanotubes with low molecular weight fluids or particles is a challenge 
faced in numerous applications. We recently discovered that self-sustained 
diffusion at room temperature and atmospheric pressure in a droplet of dilute 
polymer solution or nanoparticle suspension allows for intercalating several-
micron-long nanotubes with polymers, surfactants and nanoparticles with no 
harm for biologically active species. The method also allows for intercalating 
nanotubes with drugs sealing them with NIPAM-based thermo- and pH-
responsive caps. This allows, in principle, creating nanobots: nanotubes 
intercalated with anti-cancer drugs, which release them only near a tumor in 
response to pH stimulus, since tumors and inflammated places are typically 
more acidic (pH 6.5) than normal tissues (pH 7.4).  www.scipharm.at Scientia  Pharmaceutica  543 
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Almost alone among the process industries, the pharmaceutical industry has 
tended to rely on batch operations. This is now changing, driven by a need for 
better utilisation of resources, particularly clean space, and a demand for more 
closely controlled processes. Process Analytical Technology (PAT) demands 
that processes be controlled; this is much more easily engineered into 
continuous processes. 
Wet granulation presents a particular problem, in that it has traditionally been 
carried out in a high-shear mixer-granulator and is not particularly well 
understood. What is known is that the mechanisms of nucleation, consolidation, 
growth and breakage occur more-or-less simultaneously in a high shear 
environment, and in a relatively uncontrolled way. In principle, it would be highly 
attractive to separate these basic mechanisms so that they occur within a 
continuous process in a controlled way.  
This paper proposes the practical development of an overall process for 
continuous pharmaceutical manufacture, with consideration of process control, 
instrumentation, validation and real-time product release. 
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Most currently produced pharmaceutical formulations are based on a single 
molecular entity – the active pharmaceutical ingredient (API) – that is 
synthesised in a dedicated (bio)chemical plant and then has to be stable 
throughout the supply chain all the way to the patient. However, many 
pathogens that the API is supposed to fight use a different strategy: they 
produce toxins locally within the host and the timing, quantity and even 
composition of the toxins can vary from host to host and depending on local 
conditions. 
The aim of our work is to design and synthesise structured microparticles called 
chemical robots that are inspired by the structure and function of single-cell 
organisms. A chemical robot consists of an outer semi-permeable shell and 
several internal separate compartments able to store and release chemical 
reagents on demand. A predefined set of chemical or enzymatic reactions take 
place within the body of the chemical robot and the reaction product is released 
to the outside environment at a predefined rate. The chemical robot can 
therefore be thought of as a miniature chemical reactor with internal supply of 
reactants and a mechanism for triggering their release. 
The synthesis of chemical robots follows a bottom-up strategy. In the first step, 
the internal compartments (either based on liposomes or on hollow mesoporous 
silica particles) are synthesised and pre-filled with the required reagents. 
Compartments containing different reagents are then mixed in a colloidal 
suspension called “roboplasma” (like cytoplasma), which is then encapsulated 
into the external membrane by means of either inkjet printing technology [1] or 
interfacial polymerisation [2]. Finally, the outer surface of the chemical robots 
can be functionalised by attaching the desired functional groups e.  g. for 
specific ligand-receptor binding. In this presentation the current status of 
chemical robot synthesis and functionality will be reviewed and some 
challenges for further research in this area will be outlined. 
This work is supported by the European Research Council through grant 
number 200580-Chobotix. 
[1]  Dohnal J, Stepanek F. Inkjet fabrication and characterization of calcium alginate microcapsules. 
Powder Technol. 2010; 200: 254–259. doi:10.1016/j.powtec.2010.02.032 
[2]  Cejkova J, Hanus J, Stepanek F. Investigation of internal microstructure and thermo-responsive 
properties of composite PNIPAM/silica microcapsules. J Coll Interf Sci. 2010; 346: 352–360. 
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Inflammatory bowel diseases, such as Morbus Crohn or Colitis Ulcerosa, are 
painful for the patient and moreover difficult to treat due to the increased mucus 
production and the occurrence of diarrhea. We could demonstrate that the anti-
inflammatory drug rolipram, when delivered by nanoparticles made of 
biodegradable PLGA, led to a prolonged alleviation of colitis syndromes in rats 
and a reduction of central nervous side effects, compared to the same dose of 
the drug administered as an aqueous solution [1, 2].  
With respect to skin drug delivery, there is an interesting new hypothesis that 
nanoparticles may penetrate along hair shafts and to thus accumulate in hair 
follicles [3]. However, applying PLGA nanoparticles loaded with flufenamic acid, 
were mostly seen in the intercellular clefts between the keratinocytes [4]. The 
observed enhancement of epidermal penetration may instead be explained by 
an acidic microclimate around the hydrolyzing polymer particles, leading to a 
reduced dissociation and higher lipophilicity/better penetration of flufenamic acid 
[5]. This data points out that, besides of their small size, the chemical com-
position of such nanomaterials remains evenly important.  
Due to their large surface area and excellent blood supply, the lungs are an 
attractive alternative route for drug delivery, both for local as well as for 
systemic action. By escaping mucociliary or macrophage clearance, inhaled 
nanopharmaceuticals could perhaps be used as platform for pulmonary 
sustained release delivery systems. Finally, nanoplexes formed between 
biodegradable polymeric carriers and DNA/RNA-based drugs can be used to 
facilitate cellular transfection [6]. We are currently using this approach for the 
delivery of telomerase inhibiting antisense oligonucleotides to lung cancer cells 
[7, 8].  
[1]  Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers 
to the inflamed colonic mucosa. Pharm Res. 2001; 18: 788–793. doi:10.1023/A:1011032328064 
[2]  Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. 
Biodegradable nanoparticles for in treatment of inflammatory bowel disease. J Pharm Exp Therap. 
2001; 299: 775–781. PMid:1602694 
[3]  Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, Weiss B, Schaefer UF, 
Lehr CM, Wepf R, Sterry W. Nanoparticles - An efficient carrier for drug delivery into the hair follicles. 
Euro J Pharm Biopharm. 2007; 66: 159–164. doi:10.1016/j.ejpb.2006.10.019 
[4]  Stracke F, Weiss B, Lehr CM, König K, Schaefer UF, Schneider M. Multiphoton microscopy of dermal 
penetration of nanoparticle-borne drugs. J Invest Dermatol. 2006; 126: 2224–2233. 
doi:10.1038/sj.jid.5700374 
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Nanoparticles represent useful drug delivery systems for the specific transport 
of drugs to target cells and tissues. Over the last 30 years a multitude of 
different nanoparticle systems based on several starting materials were 
described. Recently, albumin based nanoparticles were approved by the FDA 
and EMEA as drug delivery device for tumor therapy. Most often nanoparticles 
are developed with the aim of selectively transporting a drug to a diseased 
tissue or organ. To reach this goal, such drug carrier systems may be combined 
with targeting ligands, which enable a cell-specific accumulation of the 
nanoparticles. 
Within the presentation the development of targeted nanoparticles for tumor 
therapy will be described. The preparation and characterisation of antibody-
modified protein-based nanoparticles will be focused [1]. The ability of the 
particle systems to specifically accumulate in different tumor cell models by 
receptor-mediated endocytosis will be presented [2]. 
The results indicate that protein-based nanoparticles conjugated to an antibody 
against a specific cellular epitope hold promise as selective drug delivery 
systems for the treatment of cells and tissues expressing a specific cellular 
antigen. 
[1]  Steinhauser I, Spänkuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: 
Optimisation of preparation and uptake in cancer cells. Biomaterials. 2006; 27: 4975–4983. 
doi:10.1016/j.biomaterials.2006.05.016 
[2]  Spänkuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko, E, Strebhardt K., Langer K. Down-regulation 
of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. 
Neoplasia. 2008; 10: 223–234. doi:10.1593/neo.07916 www.scipharm.at Scientia  Pharmaceutica  547 
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Nanoparticles (NP) are increasingly used in a wide range of applications in 
science, technology and medicine. Since they are produced for specific 
purposes which cannot be met by larger particles and bulk material they are 
likely to be highly reactive, in particular, with biological systems. Direct routes of 
intake into the organism are (1) inhalation and deposition of NP in the 
respiratory tract and (2) oral intake of NP and ingestion. Recently there is 
evidence that nanoparticles can cross body membranes – such as the air-
blood-barrier in lungs and the intestinal epithelium – reaching blood circulation 
and accumulating in secondary target organs. Therefore, direct intravenous 
administration of NP into circulation provides a powerful tool to shed light on the 
various interactions of crossing body membranes. 
To quantitatively determine accumulated NP fractions in such organs the 
ultimate aim is to balance the NP fractions in all interesting organs and tissues 
including the remaining body and total excretion. Since these gross 
determinations of NP contents in organs and tissues do not provide microscopic 
information on the anatomical and cellular location of nanoparticles such studies 
are to be complemented by electron microscopy analysis as demonstrated for 
inhaled titanium dioxide nanoparticles. 
Based on quantitative biokinetics after all three routes of administration in a rat 
model (lungs, blood, gastro-intestinal tract) we found small NP fractions (iridium, 
carbon, titanium dioxide, gold,) in all secondary organs studied including brain, 
heart and even in foetuses. Fractions per secondary organ were usually below 
0.1% of the administered dose but depended strongly on particle size, material 
and surface modifications as well as on the route of intake.  
The current knowledge on systemic translocation of NP and their accumulation 
in secondary target organs and tissues of man and animal models does not 
suggest to cause acute effects of translocated NP but chronic exposure may 
lead to elevated NP accumulations resulting eventually in adverse health 
effects. 
In fact, there is growing evidence that ambient ultrafine particles and some of 
the engineered NP can induce acute adverse health effects in humans and in 
animal models not only in the respiratory tract but also in the cardio-vascular-
system. Since NP translocation is so low these effects are likely to be triggered 
by mediators released in the organ of intake. 548 Scientia  Pharmaceutica  www.scipharm.at 
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Understanding the intracellular localisation of biomedical nanoparticles (NPs), 
such as their co-localisation within cellular organells, e.  g. endosomes, 
lysosomes, mitochondria or nuclei, or, alternatively free in the cytosol, can 
provide essential information in regard to the potential toxicity of NPs.  
Polymer coated iron-platinum and gold NPs with a fluorescent dye embedded in 
the polymer shell were used to investigate their intracellular localization in lung 
cells, i. e. epithelial cells, macrophages as well as dendritic cells [1], and their 
potential to induce a pro-inflammatory response dependent on concentration 
and incubation time [2]. In addition, a quantitivate method [3] was used to 
evaluate the intracellular gold NP distribution by transmission electron 
microsopy within time (1h, 4h and 24h). 
By laser scanning microscopy it was shown that the iron-platinum NP were 
taken up by all three cell types but macrophages and dendritic cells to a higher 
extent than epithelial cells. In both cell types of the defence system but not in 
epithelial cells, a particle dose-dependent increase of tumor necrosis factor-α is 
found. By comparing the iron-platinum- and the gold NPs as well as the shell 
only it was shown that the cores combined with the shells are responsible for 
the induction of inflammatory effects and not the shells alone. The quantitative 
analysis revealed a significant, non-random intracellular gold NP distribution. No 
particles were observed in the nucleus, mitochondria, endoplasmatic reticulum 
or golgi, and the cytosol was not the preferred NP compartment. A significant 
increased gold NP localization in large vesicles (lysosomes) was found with 
prolonged post-incubation times, indicating intracellular particle trafficking. 
In conclusion, by using sophisticated cell culture and microscopic methods, it is 
possible to determine if NPs exposed to cultured lung cells can penetrate into 
these cells, inducing an effect and furthermore, in which intracellular 
compartments they are subsequently localized (trafficking). 
This work was supported by the German Research Foundation (DFG SPP 
1313), the Swiss National Foundation (Nr. 3100A0_118420), the Doerenkamp 
Zbinden Foundation and the AnimalFreeResearch. 
[1]  Lehmann AD, Parak WJ, Zhang F, Ali Z, Röcker C, Nienhaus GU, Gehr P, Rothen-Rutishauser B. 
Fluorescent-magnetic hybrid nanoparticles induce a dose-dependent increase of the pro-inflammatory 
response in lung cells in vitro correlated with intracellular localization. Small. 2010; 6: 753–762. 
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Continuous processing offers many advantages in pharmaceutical 
manufacturing. Low capital investment from a small factory foot print, removal of 
scale-up issues during process development and support of agile /lean supply 
chain being key economic benefits.  
Process analytical technology is a key enabler of continuous processing of 
pharmaceuticals. The ability of rapid on-line measurement technologies reduces 
the risk of continuous mixing systems, and can support a QbD approach to 
control and lead to adoption of Real Time Release strategies for the product. 
This paper will describe the on-line PAT systems developed for, and installed in 
Pfizer’s first commercial scale continuous drug product manufacturing facility. 
The focus will be on design of sample interfaces and the measure capability 
related to the product specifications. The paper will also include a discussion on 
method validation philosophies for on-line real time technologies applied to 
pharmaceutical processes. 
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Different solid state characterization techniques have been widely used to gain 
a better understanding of the physical solid state characteristics of drug 
substances and drug formulations. In the past, physical characterization in the 
pharmaceutical industry mainly relied on x-ray powder diffraction, thermal 
analysis and microscopy. More recently, vibrational spectroscopic techniques 
such as infrared (IR), near-infrared (NIR), Raman and solid state nuclear 
magnetic resonance spectroscopy (SS-NMR) have attracted growing attention 
in both academia and industry. Even more recently, terahertz pulsed 
spectroscopy (TPS) has also been utilized to investigate pharmaceutical 
materials.  
Spectroscopic techniques possess many advantages over other traditional 
analytical techniques, for instance the fact that they allow rapid, non-destructive 
measurements, suitable for use in the process analytical technology (PAT) 
setting. In this presentation recent examples of the use of spectroscopic 
techniques especially Raman spectroscopy, NIR and TPS on characterizing 
pharmaceutical compounds and formulations will be presented. Specific 
examples from our own work will be presented in this talk.  
Using the example of the important anticonvulsant drug carbamazepine (CBZ), 
we will demonstrate that Raman spectroscopy combined with partial least 
squares (PLS) analyses can be used to quantify the conversion of CBZ 
polymorphs to the CBZ dihydrate in aqueous suspension. It was found that 
crystal morphology and polymorphic form have a large effect on the conversion, 
but that the conversion is not quantitative. An increased understanding of the 
influence of factors of this conversion such as defects, crystalline face 
differences, which are important to the physical stability of CBZ, can be 
obtained using a combination of spectroscopic and imaging techniques.  
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Coating of tablets is an important way to design properties of the final dosage 
form. The purposes for coating are manifold, e.  g. taste masking, humidity 
protection, gastric resistance, modified release, active coating. In some cases 
the coating uniformity is critical for the intended use. Therefore, it is important to 
know coating uniformity of tablets can be achieved and analysed. Several 
aspects have to be taken into account, namely the intra-tablet coating 
uniformity, the inter-tablet coating uniformity, and the batch-to-batch coating 
uniformity. 
The intra-tablet coating uniformity can be determined by different methods. One 
modern approach is the determination of coating thickness by Terahertz pulsed 
imaging. Several thousands measurements can be done to scan the total 
surface of a coated tablet. It turns out that the coating thickness is higher on the 
upper and lower surface compared with the central band. This has 
consequences for the modified drug release. From simulations the film 
distribution on the tablet surface can be estimated.  
The inter-tablet coating uniformity can also be estimated from simulations. 
These simulations are the basis for machine and process optimization in order 
to minimize the tablet-to-tablet coating variability. In case of active coating the 
content uniformity is limiting the variability. While the inter-tablet coating 
uniformity is typically determined offline first attempts are made for inline 
measurements. 
Not only the amount and distribution of coated material on the surface of a 
tablet can influence the product properties, but also the quality of the film. 
Tablets coated with the same amount of polymer can show different release 
profiles, because the film thickness differs due to different densities of the film. 
Thus, not only the film thickness is of importance but also the film structure. 
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The majority of active agents used in medicinal therapy belong to category BCS 
II, which means that they have poor dissolution and good absorption properties, 
thus their absorption can be controlled and promoted first of all with various 
formulation technologies. Melt granulation, which is a thermomechanical 
technology, is used more and more frequently for the formulation of these 
poorly soluble active agents. 
It can be considered as a possible technological operation only if the active 
agent(s) and excipients to be used are not heat-sensitive, and if the binding 
material has a solid state at room temperature but can be melted between 
about 30-90 °C. During the operation the active agent is either melted or is 
aggregated with the melt of the excipient. 
Our aim was to create an excipient system with melt granulation the 
thermoanalytical and physical properties of which correspond to the values 
required for further processing (tabletting, encapsulation), and in which active 
agents belonging to category BCS II can also be processed well. 
Melt granulation was performed with the hydrophilic Gelucire 44/14 (Gattefossé) 
lipid system, Mg-Al-silicate (Neusilin US2, Fuji Chem. Ind.) was used as a 
vehicle. Granulates were made with ProCepT high sheer granulator. The 
particle size distribution and the sphericity of the granulates was examined with 
Camsizer (Retsch Technology), their flowability with Erweka GT, the physical 
parameters of the tablets (breaking hardness, friability, disintegration) with 
Pharmatest equipment, while the dissolution studies were made with a Hanson 
apparatus. The changes in the thermoanalytical properties of the granulates 
were followed with DSC and TG (Perkin Elmer). A drug reducing appetite was 
used as an active agent. 
During our work we were successful in formulating melt granulates which 
contained a sufficient quantity of adsorbed lipids to enhance the solubility of 
BCS II active agents and also had appropriate physical properties necessary for 
tabletting. 
It was found that the yield of the granulate increases with the increase in the 
concentration of Gelucire, in addition to which its density also increases and its 
thermal stability improves. 
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Variability among individuals that affects clinical outcome is still one of the major 
challenges in drug development and in the practice of medicine. No single drug 
is 100% efficacious in all patients. While some individuals obtain the desired 
effects, there can be no or little therapeutic response in others. Additionally, 
some patients might experience adverse effects. This interindividual variability 
is a consequence of myriad of factors, such as disease states, genetic factors, 
patient age, concomitant medications, and life style factors such as smoking. 
Most drugs undergo biotransformation and their disposition in the body may 
involve multiple transport proteins. In addition, they interact with diverse protein 
targets. This concerted action results in the multigenic nature of a majority of 
drug responses. Pharmacogenomics, in the future, may provide a complex and 
more precise set of tools for clinicians to use for diagnosis and treatment. 
Extensive pharmacometric expertise and model building enables 
personalization of therapies, which is far from trivial if one considers the 
complexities of designing the most effective dosage regimen of one or more 
drugs in conjunction with novel biomarkers. Population pharmacokinetic/ 
pharmacodynamic methods, such as nonlinear mixed effects modeling are able 
to obtain relevant information in patients who are representative of the target 
population. They recognize sources of variability such as inter- and 
intraindividual as important drug characteristics, and seek to explain variability 
by identifying various covariates, including genetic factors. Additionally, they 
aim to quantitatively estimate the magnitude of the unexplained part of the 
variability, which is important because the efficacy and safety of a drug may 
decrease as unexplained variability increases. This presentation will 
demonstrate how pharmacogenetics and population pharmacokinetics can 
personalize treatment with warfarin, leflunomide [1], and risperidone [2].  
[1]  Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomšič M, Šuput D, Trdan T, Peterlin-Mašič L, 
Mrhar A, Dolžan V. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 
2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide (A77 1726) pharmacokinetics in 
leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos. 2009; 37: 2061–2068. 
doi:10.1124/dmd.109.027482 
[2]  Kastelic M, Koprivšek J, Kores-Plesničar B, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolžan V. 
MDR1 gene polymorphisms and response to acute risperidone treatment. Progr 
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The dramatic changes in the demographics will increase the number of elderly 
people from today’s 10 % to 20% of the population in 2050, which is considered 
of one of the biggest challenge for our society. Geriatric therapeutic care is a 
multidisciplinary task that starts early on in the therapy of older adults and 
involves all stakeholders, including the patient, clinicians, physician, pharmacist, 
nurse, pharmaceutical industry and sciences and health care providers and 
policy makers [1]. When chronic diseases develop along with the increasing age 
and people start to take regularly medicines. With other diseases or symptoms 
occuring additional medications are given in the best intend of curing. Various 
physiological, biological, physical and social functions are changing with age 
too, leading to an increasingly heterogeneous patient group of the people 65 
years and older. With 30–50% of all prescription drugs elderly patients 
represent the majority of drug users; however, their needs are poorly 
recognized in drug products development as well as their perception on 
medicines and their individual goals in drug prescription and therapy. Changes 
in the physiological and functional capacities, declining cognitive functions, 
impaired vision [2], increasing motoric limitations [3], an increasing difficulty of 
swallowing [4] and an increasing number of chronic diseases occurs with age. 
Within our drug product development programs the needs of special patient 
populations like elderly have to be taken into consideration. Age related 
changes need to be better understood and integrated into an overall therapeutic 
care plan that reflects the patient expectations and goals in the therapy as well 
as the patient life style to be executable.  
The author would like to thank all members of the ‘Geriatric Medicines Society’ 
for the contributions to this paper. 
[1]  Stegemann S, Ecker F, Maio M, Kraahs P, Wohlfart R, Breitkreutz J, Zimmer A, Bar-Shalom D, 
Hettrich P, Broegmann B. Geriatric drug therapy: Neglecting the inevitable majority. Ageing Res Rev. 
2010; in press. doi:10.1016/j.arr.2010.04.005 
[2]  Evans JR, Fletcher AE, Wormald RP, Ng ES, Stirling S, Smeeth L, Breeze E, Bulpitt CJ, Nunes M, 
Jones D, Tulloch A. Prevalence of visual impairment in people aged 75 years and older in Britain: 
results from the MRC trial of assessment and management of older people in the community. Br J 
Ophthalmol. 2002; 86, 795–800. doi:10.1136/bjo.86.7.795 
[3]  Atkin PA, Finnegan TP, Ogle SJ, Shenfield GM. Functional ability of patients to manage medication 
packaging: A survey of geriatric inpatients. Age Ageing. 1994; 23: 113–116. 
doi:10.1093/ageing/23.2.113 
[4]  Sheth N, Diner WC. Swallowing problems in the elderly. Dysphagia. 1988; 2: 209–215. 
doi:10.1007/BF02414428 